Effect of plinabulin, a novel late-clinical stage immunotherapeutic agent on the adaptive and innate immune system. This is an ASCO Meeting Abstract from the 2020 ASCO-SITC Clinical Immuno-Oncology ...

Despite potential benefits, the therapy remains in limited use for myeloproliferative neoplasms (MPNs). Pegylated interferons are a meaningful therapeutic option for the treatment of ...

A growing body of research has identified a hidden immune defect, not written in DNA, that helps explain why certain people ...

In 1980, TIME Magazine wrote about interferon as the “if” drug for cancer. Promising studies sparked widespread hope around the potential of the interferon to treat cancer, only if it could deliver ...

Known as first responders to viral infection, Type I interferons may also play a part—for better or worse—in neurodegenerative disease. At AD/PD 2022, held March 15-20 online and in Barcelona, Spain, ...

Multiple sclerosis is a chronic neurodegenerative disorder caused by the body’s autoimmune attack of the protective covering that surrounds nerves in the body. This substance is called myelin and ...

Dendritic cells require a special 'license' to present exogenous antigens to CD8 + T cells. Such permission may be provided by type I interferons during viral infections. Although these studies ...

In severe cases of COVID-19, a person’s immune system throws everything it has at the coronavirus, but some of the weapons it lobs end up hurting the patient instead of fighting the virus. Now ...

A new study shows that about two percent of the population develop autoantibodies against type 1 interferons, mostly later in life. This makes individuals more susceptible to viral diseases like COVID ...

Over the past decade, the pharmaceutical pipeline has become packed with small molecules that treat the hepatitis C virus (HCV). Hopes are high that the current standard of care—a combination of ...